SCHEMBL606837

SCHEMBL606837

OC(CN1CCN(CC2CO2)CC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BAX Q07812 2/20 0.66
MAPT P10636 5/20 0.65
TP53 P04637 2/20 0.65
MAPK1 P28482 2/20 0.65
CYP3A4 P08684 1/20 0.65
ALOX15 P16050 1/20 0.65
RAD52 P43351 2/20 0.62
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
DNM1 Q05193 4/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HTT P42858 3/20 0.51
NPSR1 Q6W5P4 3/20 0.51
LMNA P02545 2/20 0.51
ALDH1A1 P00352 1/20 0.51
NLRP1 Q9C000 1/20 0.49
P2RX3 P56373 1/20 0.48
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6819686 0.88 BAX (0.82) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL607458 0.83 RAD52 (0.66) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL16210953 0.82 BAX (0.72) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL6815606 0.82 MEN1 (0.88) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL608466 0.81 BAX (0.67) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL609179 0.81 BAX (0.67) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL5025353 0.81 BAX (0.67) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL7652515 0.80 MAPT (0.53) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL410834 0.80 DNM1 (0.73) BAXMAPTTP53MAPK1CYP3A4
SCHEMBL609455 0.80 BAX (1.00) BAXMAPTTP53MAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed
EP-1094063-A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators Applied Research Systems ARS Holding N.V. (AN) 2001-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD BAX 2/4885MAPT 1085/4885TP53 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.